Citius Pharmaceuticals (STU:47N0) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:47N0 Citius Pharmaceuticals Inc STU:47N0
25 GF Score
Price €3.29
! 2 Warning Signs
View Full Analysis

What is Citius Pharmaceuticals LT-Debt-to-Total-Asset?

Citius Pharmaceuticals STU:47N0 25 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates STU:47N0 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Citius Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

Citius Pharmaceuticals's long-term debt to total assets ratio declined from Mar. 2025 (0.01) to Mar. 2026 (0.01). It may suggest that Citius Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Citius Pharmaceuticals  (STU:47N0) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Citius Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Citius Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Citius Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Pharmaceuticals LT-Debt-to-Total-Asset Chart

Citius Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.01

Citius Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01
STU:47N0
25GF Score
Citius Pharmaceuticals Inc STU:47N0
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Citius Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (A: Sep. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2025 )/Total Assets (A: Sep. 2025 )
=0.618/111.559
=

Citius Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0.551/114.648
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Citius Pharmaceuticals (STU:47N0) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Citius Pharmaceuticals and its competitors.
Is Citius Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Citius Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.01. Overall, Citius Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Citius Pharmaceuticals' LT-Debt-to-Total-Asset compare to LEXX and HIND?
Citius Pharmaceuticals' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Citius Pharmaceuticals and its competitors. Citius Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Pharmaceuticals stock overvalued right now?
Citius Pharmaceuticals (STU:47N0) has a current LT-Debt-to-Total-Asset of 0.01. The current LT-Debt-to-Total-Asset is 0.01. Citius Pharmaceuticals' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Citius Pharmaceuticals (STU:47N0), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Pharmaceuticals Business Description

Other Exchanges CTXR:USA
Address 11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
25GF Score

Get the complete analysis for STU:47N0

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.29
Price